Cancer. Cancer immunotherapy is more than a numbers game.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma.Oncotarget · 2018
   Article
2. Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.Oncoimmunology · 2015
   Article
3. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2012
   Article
4. IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments.Clinical immunology (Orlando, Fla.) · 2009
   Article
5. Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors.Cancer immunology, immunotherapy : CII · 2008
   Article
6. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.Journal of virology · 2008
   Article
7. Therapeutic anti-tumor vaccines: from tumor inhibition to enhancement.Clinical medicine. Oncology · 2008
   Article
8. Prostate cancer: genes, environment, immunity and the use of immunotherapy.Prostate cancer and prostatic diseases · 2008
   Review
9. Emerging Challenges to Cellular Therapy of Cancer.Cancer journal (Sudbury, Mass.)
   Review

Corrections and comments

• Comment on
  Cancer regression in patients after transfer of genetically engineered lymphocytes.2006

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as